Michael Yim, MD
Ophthalmology · Miami, FLNPI 1669816864
Payments from drug & device makers
Across 338 payments — averaging $477.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$59K
- Alcon$47K
- Sight Sciences, Inc.$45K
- Ivantis, Inc$4K
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$1K
- plus $4K from 19 others
What the payments were for
- Consulting fees$15,39210%
- Speaking & faculty fees$125,42178%
- Travel & lodging$7,4925%
- Food & beverage$12,9178%
- Other$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 60 | $59,338 |
| Alcon | 72 | $46,555 |
| Sight Sciences, Inc. | 60 | $44,996 |
| Ivantis, Inc | 7 | $3,587 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $2,131 |
| AbbVie(2 entities) | 40 | $1,058 |
| Glaukos Corporation | 11 | $811 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $741 |
| Sun Pharmaceutical Industries Inc. | 13 | $324 |
| Bausch & Lomb Americas Inc. | 6 | $261 |
| Eyevance Pharmaceuticals LLC | 3 | $198 |
| GSK | 10 | $160 |
| Amgen(2 entities) | 6 | $151 |
| NEW World Medical,inc. | 2 | $145 |
| Shire North American Group Inc | 4 | $133 |
| Oyster Point Pharma, Inc. | 2 | $124 |
| Regeneron Healthcare Solutions, Inc. | 1 | $116 |
| Novartis | 6 | $87 |
| Hoffmann-la Roche Limited | 1 | $81 |
| Tarsus Pharmaceuticals, Inc. | 3 | $67 |
| Kala Pharmaceuticals, Inc. | 4 | $57 |
| Johnson & Johnson Vision Care, Inc. | 3 | $54 |
| Beaver-visitec International, Inc. | 1 | $31 |
| Welch Allyn | 1 | $19 |
| Harrow Eye, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$101,813
- Rhopressa$98,337
- OMNI(R) SURGICAL SYSTEM (US)$44,198
- SION SURGICAL INSTRUMENT$26,805
- SIMBRINZA$9,336
- Hydrus Microstent$3,533
- Tecnis Multifocal Family of 1-piece IOLS$1,789
- Tecnis 1-piece IOL$1,664
- Tecnis Symfony IOL$1,664
- VYZULTA$512
- XEN GLAUCOMA TREATMENT SYSTEM$339
- iStent inject Trabecular Micro-Bypass Stent System$296
- iStent inject W$276
- Flarex$155
- TORIC$151
- Centurion$150
- XEN$144
- ReSTOR$141
- ARGOS$140
- KXL System$133
How this compares
$161,241 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 208 | $169,502 |
| RhopressaNetarsudil Mesylate | 170 | $141,278 |
| RestasisCyclosporine | 65 | $89,488 |
| VyzultaLatanoprostene Bunod | 89 | $59,816 |
| LumiganBimatoprost | 49 | $40,202 |
| CequaCyclosporine | 25 | $32,933 |
| Latanoprost | 1,103 | $32,288 |
| CombiganBrimonidine Tartrate/Timolol | 48 | $24,273 |
| Alphagan PBrimonidine Tartrate | 36 | $22,897 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 48 | $18,453 |
| Timolol Maleate | 236 | $13,393 |
| Brinzolamide | 43 | $12,252 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 588 | $11,237 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,362 |
| Brimonidine Tartrate | 176 | $9,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $59,338 | $310,780378 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,058 | $176,860198 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $261 | $70,178103 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $324 | $32,93325 claims |
| AlconSimbrinza | $46,555 | $18,45348 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $741 | $4,70516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Miami
- Guillermo AmescuaMiami$962K
- Felipe MedeirosMiami$935K
- Jennifer LohMiami$606K
- Jaclyn KovachMiami$590K
- William TrattlerMiami$580K
- Wilfredo LaraMiami$526K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$351K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.